Genetically Modified Escherichia coli Nissle 1917 Producing Anti-TNF-α Nanobody as a Novel Single-Strain Live Biotherapeutic for Treating Inflammatory Bowel Disease
By
Qiumei Zhu
Shitao Feng
Zhende Yan
Zijian Wang
Xinran Huang
Changning Sun
Bingqiang Zhang
Xinrui Li
Yuchao Gu
July 2, 2026
Clinical Scorecard: Genetically Modified Escherichia coli Nissle 1917 Producing Anti-TNF-α Nanobody as a Novel Single-Strain Live Biotherapeutic for Treating Inflammatory Bowel Disease
At a Glance
Category Detail
Condition Inflammatory Bowel Disease (IBD) Key Mechanisms Localized TNF-α neutralization via engineered probiotics Target Population Patients with IBD, including Crohn’s disease and ulcerative colitis Care Setting Clinical settings for IBD treatment
Key Highlights
EcN-MT1 significantly reduced weight loss and improved disease activity index in murine colitis models. Engineered EcN demonstrated high secretion levels of anti-TNF-α nanobody MT1. Treatment restored gut microbial diversity and corrected dysbiosis. EcN-MT1 showed potent suppression of pro-inflammatory cytokines in macrophages. The study highlights the potential of live biotherapeutics for safer IBD therapies. Guideline-Based Recommendations
Diagnosis
Diagnosis of IBD should consider clinical, endoscopic, and histological criteria. Management
Consider engineered probiotics like EcN-MT1 for localized treatment of IBD. Monitoring & Follow-up
Monitor disease activity index and mucosal healing in IBD patients. Risks
Current treatments carry risks of systemic immunosuppression and opportunistic infections. Patient & Prescribing Data
Patients with chronic inflammatory bowel disease.
EcN-MT1 offers a novel approach by delivering localized anti-inflammatory effects without systemic exposure.
Clinical Best Practices
Utilize engineered probiotics for targeted therapy in IBD. Assess gut microbiota diversity as part of treatment evaluation. Incorporate monitoring of pro-inflammatory cytokines in treatment plans. Related Resources & Content
